CO-DEVELOPMENT, SUPPLY AND COMMERCIALIZATION AGREEMENTSupply and Commercialization Agreement • May 7th, 2021 • Ocugen, Inc. • Biological products, (no disgnostic substances)
THIS CO-DEVELOPMENT, SUPPLY AND COMMERCIALIZATION AGREEMENT (this “Agreement”) dated as of January 31, 2021 (the “Effective Date”) is entered into by and between Ocugen, Inc., with an address at 263 Great Valley Parkway, Malvern, PA 19355, USA (together with its Affiliates, subsidiaries, successors and permitted assigns, “Ocugen”), and Bharat Biotech International Limited, whose registered office address is at Genome Valley, Shameerpet, Hyderabad – 500 078 Telagana India (together with its Affiliates, subsidiaries, successors and permitted assigns, “BBIL”). Ocugen and BBIL may be referred to herein as a “Party” or, collectively, as “Parties”.
OCUGEN, INC. PERFORMANCE-VESTED STOCK OPTION AGREEMENTPerformance-Vested • May 7th, 2021 • Ocugen, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS PERFORMANCE-VESTED STOCK OPTION AGREEMENT (“Agreement”) is made and entered into as of _____________ (the “Grant Date”), by and between Ocugen, Inc., a Delaware corporation (the “Company”), and ________________, an individual (the “Optionee”).
